About: Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial
Creator	De, Adolphe Désilles, Jean-Philippe Houdas, Sophie
Source	Medline; PMC
abstract	OBJECTIVES: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) may trigger severe pneumonia in coronavirus disease of 2019 (COVID-19) patients through release of damage-associated molecular patterns (DAMPs) and recruitment of neutrophils in the lungs. Activated neutrophils induce inflammation and severe alveolar injury by releasing neutrophil extracellular traps (NETs). The backbones of many DAMPs and NETs are made of extracellular, cell-free DNA decorated with highly toxic compounds such as elastase, myeloperoxidase and citrullinated histones. Dornase alfa is a FDA-approved recombinant human DNAse 1 for the treatment of cystic fibrosis, which cleaves extracellular DNA and may break up cell-free DNA, loosening sticky mucus in the distal airways and reducing NETs-induced toxicity on alveolar pneumocytes. The COVIDornase trial intends to define the impact of aerosolized intra-tracheal dornase alfa administration on the severity and progression of acute respiratory distress syndrome (ARDS) in COVID-19 patients. This drug might make lung mucus thinner and looser, promoting improved clearance of secretions and reduce extracellular double-stranded DNA-induced hyperinflammation in alveoli, preventing further damage to the lungs. TRIAL DESIGN: COVIDornase is a prospective, randomized, controlled, 2-arm (1:1 ratio), multicentric, open-label clinical trial. PARTICIPANTS: The study will recruit mechanically ventilated patients hospitalized in the intensive care unit (ICU) in the recruiting centres (at the time of writing: The Rothschild foundation hospital in Paris, the Strasbourg university hospitals, and Metz-Thionville hospital) who have been diagnosed with COVID-19 and meet ARDS criteria. INCLUSION CRITERIA: - Adult patient (age ≥ 18 years old); - Hospitalized in ICU; - With severe COVID-19 pneumonia and ARDS according to Berlin criteria (PaO(2)/FiO(2) < 300 and PEEP > 5 cmH(2)O); - Intubated for less than 8 days; - With an anticipated duration of mechanical ventilation > 48 hours; - Carrier of an arterial catheter; - For whom 4 PaO(2)/FiO(2) values over the preceding 24 hours are available; NON-INCLUSION CRITERIA: - Known hypersensitivity to dornase alfa or any of its excipients; - Pregnant or breastfeeding status; - Patient under legal protection. INTERVENTION AND COMPARATOR: Intervention 1, Study group Dornase alfa (Pulmozyme®, Roche, Switzerland) will be administered by aerosol, at a dose of 2500 IU twice daily, 12 hours apart, for 7 consecutive days, using a vibrating mesh nebulizer (Aerogen Solo®, Aerogen, Ireland). The remainder of the management will be performed in accordance with good clinical practice, including mechanical ventilation (protective ventilation, PEEP > 5 cmH(2)O, tracheal balloon pressure check every 4 hours or automatic device, 30° head of the bed elevation, tidal volume 6-8mL/kg, plateau pressure < 30 cmH(2)O), neuromuscular blockers if necessary, prone position if PaO(2)/FiO(2) < 150, early enteral nutrition, glycemic control and a sedation protocol based on the RASS score. Intervention 2, Comparator Patients will receive usual care in accordance with good practice (as detailed above), without aerosols. MAIN OUTCOMES: The primary outcome is the occurrence of at least one grade improvement between D(0) (inclusion) and D(7) in the ARDS scale severity (Berlin criteria). For instance from “severe” to “moderate” or from “moderate” to “mild”. RANDOMISATION: All consecutive patients meeting the inclusion criteria will be randomised 1:1 using an eCRF-based, computer-generated randomisation table, either to the dornase alfa arm or to the control arm. An interim analysis will be performed after inclusion of 20 patients. Inclusions may be stopped at the interim analysis per data safety and monitoring board (DSMB) advice, if statistical analyses conclude on the futility or efficacy of the intervention or by other DSMB decision. BLINDING (MASKING): The participants and caregivers will not be blinded to study group assignment. Those assessing the outcomes will be blinded to study group assignment. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): Fifty patients will be randomized to each group, 100 patients in total. TRIAL STATUS: Protocol version number 2, April 29(th), 2020. Recruitment is ongoing. The trial started recruitment on the 21(st) April 2020. We estimate recruitment will finish August 21(st) 2020. TRIAL REGISTRATION: The trial was registered in ClinicalTrials.gov on 21 April 2020, updated on 8 May 2020. Trial registration number is NCT04355364. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated. This Letter serves as a summary of the key elements of the full protocol.
has issue date	2020-06-19(xsd:dateTime)
bibo:doi	10.1186/s13063-020-04488-8
bibo:pmid	32560746
has license	cc-by
sha1sum (hex)	5173f1cbc89fffc802ee12fad8fd4de98707ba19
schema:url	https://doi.org/10.1186/s13063-020-04488-8
resource representing a document's title	Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial
has PubMed Central identifier	PMC7303591
has PubMed identifier	32560746
schema:publication	Trials
resource representing a document's body	covid:5173f1cbc89fffc802ee12fad8fd4de98707ba19#body_text
is schema:about of	named entity 'PAGE' named entity 'sans' named entity 'INT' named entity 'INFECTION' named entity 'pilote' named entity 'ANSM' named entity 'le potentiel' named entity 'Objectifs' named entity 'dornase alfa' named entity 'les éléments' named entity 'COVID-19' named entity 'objectifs' named entity 'FiO2' named entity 'NETs' named entity 'dornase alfa' named entity 'Berlin' named entity 'NETs' named entity 'ANSM' named entity 'téléphone' named entity 'ITT' named entity 'infection' named entity 'autorisés' named entity 'Pulmozyme' named entity 'les éléments' named entity 'ANSM' named entity 'COVID-19' named entity 'jugera' named entity 'Dornase alfa' named entity 'EudraCT' named entity 'Dornase alfa' named entity 'ANSM' named entity 'clinicaltrials.gov' named entity 'dispositif' named entity 'enceinte' named entity 'mis' named entity 'infection' named entity 'Les éléments' named entity 'PaO2/FiO2' named entity 'NETs' named entity 'signaler' named entity 'neutrophil extracellular traps' named entity 'cmH2O' named entity 'ANSM' named entity 'dornase alfa' named entity 'la stratégie' named entity 'dispositif' named entity 'mis' named entity 'mise en place' named entity 'nutrition' named entity 'enzyme' named entity 'le potentiel' named entity 'COVID-19' named entity 'PaO2/FiO2' named entity 'type 1' named entity 'Pulmozyme' named entity 'mucus' named entity 'dornase alfa' named entity 'COVID-19' named entity 'PaO2' named entity 'Cette' named entity 'cmH2O' named entity 'PaO2/FiO2' named entity 'infection' named entity 'Titre' named entity 'SECONDAIRE' named entity 'CORONAVIRUS' named entity 'pharmacovigilance' named entity 'RESPIRATOIRE' named entity 'DORNASE ALPHA' named entity 'TITRE' named entity 'RECHERCHE' named entity 'PHARMACOVIGILANCE' named entity 'SIGNATURE' named entity 'SANS' named entity 'FIGURANT' named entity 'par' named entity 'infection' named entity 'Code' named entity 'Rothschild'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software